Funding
Funding not disclosed
Founders
Product
Problem
Multiple sclerosis (MS) lacks effective therapies that address the underlying causes of disease progression, leaving a significant unmet need for treatments that can slow or halt the advancement of the condition and improve long-term patient outcomes. Current treatments often focus on managing symptoms rather than targeting the root mechanisms driving the disease.
Solution
Astoria Biologica is developing novel therapeutic interventions designed to target the fundamental biological processes that contribute to multiple sclerosis. Their research aims to create targeted treatments that can slow disease progression by addressing the underlying causes of MS. By focusing on the root mechanisms, Astoria Biologica seeks to develop therapies that offer a more effective and sustainable approach to managing the disease and improving patient outcomes.
Target Audience
The primary target audience includes individuals diagnosed with multiple sclerosis and the healthcare professionals who treat them, such as neurologists and MS specialists.
Features
- Development of targeted therapies for multiple sclerosis
- Focus on addressing the underlying causes of disease progression
- Research aimed at slowing or halting the advancement of MS